Oncocyte Corporation Ocx Stock Price, News, Quote & History


Poster outlines data showing Oncocyte’s DetermaIO™ tool can inform therapeutic decisions and has the potential to improve outcomes for patients with… Live educational sessions using site features to explore today’s markets. Realtime quote and/or trades are not sourced from all markets. There may be delays, omissions, or inaccuracies in the Information.

Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Needham analyst Michael Matson maintained a Buy rating on OncoCyte (OCX – Research Report) today and set a price target of $5.00. The company’s shares closed last Tuesday at $2.19, close to its 52-week low of $1.80. According to TipRanks.com, Matson is a 4-star analyst with an average return of 8.7% and a 53.6% success rate.

Data may be intentionally delayed pursuant to supplier requirements. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. By creating a free account, you agree to our terms of service.

OncoCyte Corp holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. “OCX” stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. As of 2022 April 08, Friday current price of OCX stock is 1.385$ and our data indicates that the asset price has been in a downtrend for the past 1 year . View our full suite of financial calendars and market data tables, all for free. Real-time analyst ratings, insider transactions, earnings data, and more. MarketBeat’s community ratings are surveys of what our community members think about OncoCyte and other stocks.

In the past three months, OncoCyte insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $152,400.00 in company stock and sold $0.00 in company stock. OncoCyte has only been the subject of 3 research reports in the past 90 days. Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat’s FREE daily newsletter. Advanced charts with more than 100 technical indicators, tools and studies will give you the edge, making it easier to negotiate the market and its swings. Mutual Funds have increased holdings from 3.73% to 4.02% in Dec 2021 qtr.

Fusion Mediawould like to remind you that the data contained in this website is not necessarily real-time nor accurate. Data supports the use of DetermaIO as a pan-cancer diagnostic tool, now addressing an unmet need for patients with triple negative breast cancer, the most… Gives Oncocyte Corp an overall rank of 43, which is below average. Oncocyte Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock’s chart. A rank of 43 means that 57% of stocks appear more favorable to our system. The Score for OCX is 36, which is 28% below its historic median score of 50, and infers higher risk than normal.

At the end of my 7 days, my credit card will be conveniently charged $397/quarterly until I cancel. To see all exchange delays and terms of use, please see disclaimer. Below are the latest news stories about Oncocyte Corp that investors may wish to consider to help them evaluate OCX as an investment opportunity.

OncocyteCorporation targets for this week are 5.41, 6.84 on the upside, and 4.43, 2.26 on the downside. The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some caracas venezuela christmas key insights as we drill into the specifics of these quality attributes.OCX has a Quality Grade of F, ranking ahead of 0.09% of graded US stocks. Oncocyte Corp’s shareholder yield — a measure of how much capital is returned to stockholders via dividends and buybacks — is -58.46%, greater than the shareholder yield of only 7.56% of stocks in our set.

Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings. The word on The Street in general, suggests a Strong Buy analyst consensus rating for OncoCyte with a $4.05 average price target, which is a 105.6% upside from current levels. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence . Some negative signals were issued as well, and these may have some influence on the near short-term development.

The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study.